A parent in Delhi pays ₹8 lakh for a "stem cell cure" for their autistic child.
A man in Mumbai spends his retirement on an unproven spinal injury "therapy."
Neither treatment is approved.
Neither is properly regulated.
And until this week… neither was clearly illegal either.
That grey zone just got shut.
The Union Health Ministry has amended the Drugs Rules, 1945 — pulling stem cell products, gene therapies, and xenografts under the Central Licence Approving Authority.
One uniform framework. One national gatekeeper.
For the first time. Ever.
Here's the wild part.
Stem cell products were classified as "new drugs" back in 2018.
But the Rules had no dedicated forms to actually license their manufacture.
So clinics across India ran wild — selling "miracle" cures for:
Charging lakhs. Promising the moon. Answering to no one.
Rules 75, 75A, 76 and 76A — all rewritten.
New forms. New pathway. New accountability.
The framework will now cover:
But stay with me — this is NOT auto-approval.
Manufacturers still have to prove safety, quality, efficacy. Still need trials. Still need marketing clearance.
The Ministry made that crystal clear.
India's regulatory system was built for generics — comparing new drugs to already-approved ones.
That model breaks the moment you're dealing with living cells and rewritten DNA.
The cracks showed in 2023 when ImmunoACT's NexCAR19 — India's first homegrown CAR-T therapy — got approved… while regulators were literally figuring out the standards during the review.
And get this: NexCAR19 costs around ₹40 lakh.
Sounds huge. Until you learn the same therapy in the US runs at roughly 10x that price. 🤯
Since then, the pipeline has exploded:
All previously assessed case-by-case. No formal pathway. Pure improvisation.
More rules = more compliance = longer timelines.
Smaller biotech firms will feel the squeeze first.
And the deeper problems remain untouched:
Still — this is the moment India stopped treating frontier medicine like an afterthought.
The wild-west era of "stem cell" clinics is closing.
The era of accountable, world-class cell and gene therapy just opened its front door.
That's all for now!
